DE69832055D1 - Transdermales abgabesystem - Google Patents

Transdermales abgabesystem

Info

Publication number
DE69832055D1
DE69832055D1 DE69832055T DE69832055T DE69832055D1 DE 69832055 D1 DE69832055 D1 DE 69832055D1 DE 69832055 T DE69832055 T DE 69832055T DE 69832055 T DE69832055 T DE 69832055T DE 69832055 D1 DE69832055 D1 DE 69832055D1
Authority
DE
Germany
Prior art keywords
delivery system
transdermal delivery
transdermal
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832055T
Other languages
English (en)
Other versions
DE69832055T2 (de
Inventor
Uri Wormser
Amnon Sintov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ben Gurion University of the Negev Research and Development Authority Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Ben Gurion University of the Negev Research and Development Authority Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University of the Negev Research and Development Authority Ltd filed Critical Ben Gurion University of the Negev Research and Development Authority Ltd
Publication of DE69832055D1 publication Critical patent/DE69832055D1/de
Application granted granted Critical
Publication of DE69832055T2 publication Critical patent/DE69832055T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69832055T 1997-05-29 1998-05-04 Transdermales abgabesystem Expired - Lifetime DE69832055T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12094397 1997-05-29
IL12094397A IL120943A (en) 1997-05-29 1997-05-29 A system for administering drugs through the skin
PCT/IL1998/000205 WO1998053847A1 (en) 1997-05-29 1998-05-04 Transdermal delivery system

Publications (2)

Publication Number Publication Date
DE69832055D1 true DE69832055D1 (de) 2005-12-01
DE69832055T2 DE69832055T2 (de) 2006-07-20

Family

ID=11070190

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832055T Expired - Lifetime DE69832055T2 (de) 1997-05-29 1998-05-04 Transdermales abgabesystem

Country Status (7)

Country Link
US (1) US6274166B1 (de)
EP (1) EP0975357B1 (de)
JP (1) JP2002501524A (de)
AU (1) AU7077098A (de)
DE (1) DE69832055T2 (de)
IL (1) IL120943A (de)
WO (1) WO1998053847A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667052B2 (en) * 1997-05-29 2003-12-23 Ben Gurion University Of The Negev Research And Development Authority Transdermal delivery system
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
WO2000043058A1 (en) * 1999-01-22 2000-07-27 Powderject Research Limited Method of enhancing needleless transdermal powdered drug delivery
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2422865C (en) 2000-08-16 2012-10-16 The General Hospital Corporation D/B/A Massachusetts General Hospital Aminolevulinic acid photodynamic therapy for treating sebaceous gland disorders
CN100374457C (zh) 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1572724A4 (de) 2002-03-01 2007-03-14 Dyax Corp Kdr und vegf/kdr bindungspeptide und ihre verwendung bei der diagnose und therapie
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US7383084B2 (en) * 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8133505B2 (en) * 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) * 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7662404B2 (en) * 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
AU2004217894B2 (en) 2003-03-03 2010-07-15 Bracco International B.V. Peptides that specifically bind HGF receptor (cMet) and uses thereof
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
MXPA06011425A (es) 2004-03-31 2007-03-12 Johnson & Johnson Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
ES2710289T3 (es) 2005-06-30 2019-04-24 Janssen Biotech Inc Anticuerpos anti-IL-23, composiciones, procedimientos y usos
RS60616B1 (sr) 2005-12-29 2020-09-30 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, postupci i upotrebe
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
ES2454974T3 (es) 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
WO2011121496A1 (en) 2010-03-31 2011-10-06 Wockhardt Limited Composition comprising insulin and herbal oil for transdermal or transmucosal administration
CA2801210C (en) 2010-06-19 2020-07-21 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
US9334306B2 (en) 2011-07-09 2016-05-10 The Regents Of The University Of California Leukemia stem cell targeting ligands and methods of use
EP2846825B1 (de) 2012-03-14 2021-05-05 The Regents of The University of California Behandlung von entzündlichen erkrankungen bei nichtmenschlichen säugern
JP6771282B2 (ja) 2012-05-18 2020-10-21 ヤンセン バイオテツク，インコーポレーテツド フエントキシンｉｖ変異体及びその使用方法
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
AU2014329454B2 (en) 2013-10-03 2019-01-17 Janssen Biotech, Inc. Protoxin-II variants and methods of use
EP3598980A3 (de) 2014-06-26 2020-04-15 Yale University Zusammensetzungen und verfahren zur regulierung der renalase in der behandlung von erkrankungen und störungen
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
BR112017020896A2 (pt) 2015-04-02 2018-07-10 Janssen Biotech Inc variantes de protoxina-ii e métodos de uso
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
MX2019000641A (es) 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
MA46861A (fr) 2016-11-16 2019-09-25 Janssen Biotech Inc Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
MX2019008989A (es) 2017-01-30 2019-10-09 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
EP3679145A2 (de) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren für durch chimären ligandenrezeptor (clr) vermittelte bedingte genexpression
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
SG11202005750TA (en) 2017-12-20 2020-07-29 Poseida Therapeutics Inc Vcar compositions and methods for use
MA54132A (fr) 2018-03-05 2022-04-27 Janssen Biotech Inc Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
US20210107993A1 (en) 2018-03-07 2021-04-15 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
US10961307B2 (en) 2018-09-24 2021-03-30 Janssen Biotech, Inc. Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
US20220042038A1 (en) 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CN113574066A (zh) 2019-01-15 2021-10-29 詹森生物科技公司 用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法
EA202192038A1 (ru) 2019-01-23 2021-10-05 Янссен Байотек, Инк. Композиции антител к фно для применения в способах лечения псориатического артрита
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
US20220144934A1 (en) 2019-03-14 2022-05-12 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
JP2022524860A (ja) 2019-03-14 2022-05-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
EP3938384A4 (de) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
CA3142665A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4025593A1 (de) 2019-09-05 2022-07-13 Poseida Therapeutics, Inc. Zusammensetzungen allogener zellen und verfahren zur verwendung
CA3162246A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
RU2745998C1 (ru) * 2020-01-17 2021-04-05 Акционерное Общество "Производственная Фармацевтическая Компания Обновление" Биоадгезивная антибактериальная композиция, способ ее изготовления (варианты)
JP2023515692A (ja) 2020-03-04 2023-04-13 ポセイダ セラピューティクス，インコーポレイティド 代謝性肝障害の治療のための組成物と方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2021211628A1 (en) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2022182797A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4301863A1 (de) 2021-03-04 2024-01-10 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von hämophilie
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023193010A1 (en) 2022-04-01 2023-10-05 The Regents Of The University Of California Methods of improving cancer immunotherapy
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229410A (en) * 1978-02-13 1980-10-21 Kosti Carl M Bacteriostatic deodorant water coloring toilet element
LU84485A1 (fr) * 1982-11-22 1984-06-13 Oreal Nouvelle composition anti-acneique a base de peroxyde de benzoyle et d'au moins un autre principe actif
WO1985005036A1 (en) * 1984-04-30 1985-11-21 The Trustees Of Columbia University In The City Of Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
WO1990001023A1 (en) * 1988-07-19 1990-02-08 American Biogenetics Corporation Method for solubilizing keratinaceous materials using alkaline hydrogen peroxide solution
WO1990000899A1 (en) * 1988-07-22 1990-02-08 Ciro's Touch, Ltd. Compositions and methods for treating skin conditions and promoting wound healing
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides

Also Published As

Publication number Publication date
EP0975357A1 (de) 2000-02-02
IL120943A (en) 2004-03-28
EP0975357B1 (de) 2005-10-26
US6274166B1 (en) 2001-08-14
AU7077098A (en) 1998-12-30
WO1998053847A1 (en) 1998-12-03
JP2002501524A (ja) 2002-01-15
DE69832055T2 (de) 2006-07-20
IL120943A0 (en) 1997-09-30

Similar Documents

Publication Publication Date Title
DE69832055D1 (de) Transdermales abgabesystem
ID21702A (id) Sistim dispenser
DE69821928D1 (de) Intrakardiales defibrillierungssystem
NO994837L (no) Intravesikal medikamentavleveringssystem
IS5425A (is) Læknislyf
DE59813222D1 (de) Kathetersystem
DE69825987D1 (de) Kathetersystem
DE69825982D1 (de) Spritze
DE69801983T2 (de) Verbindungssystem
DE29717429U1 (de) Bandagen-System
DE69825282D1 (de) Unterstützungsystem
NO981995D0 (no) Horisontalpumpesystem
NO993855D0 (no) Töyelig transdermalt terapeutisk system
DE69411018D1 (de) Komponentenzulieferungsanlage
ITBS970004A0 (it) Impianto di lombricoltura perfezionato
DE29713252U1 (de) Systemschacht
DE69811604D1 (de) Förderanlage
DE29721660U1 (de) Bausystem
DE29717703U1 (de) Zaunsystem
DE29701416U1 (de) Dosiersystem
DE29708900U1 (de) Schankanlage
DE29709227U1 (de) Konstruktionssystem
DE69838238D1 (de) Narkose-Beatmungssystem
DE69809193T2 (de) Signaturen-erkennungs-system
FI970053A (fi) Transdermaalinen lääkeaineen antosysteemi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DE

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

8330 Complete renunciation